Compare Gilead Sciences, Inc. (GILD) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vanguard High Dividend Yield ETF — how do they compare? Gilead Sciences, Inc. trades at $136.55 (market cap $163.51B), while Vanguard High Dividend Yield ETF trades at $160.72. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while Vanguard High Dividend Yield ETF pays none, and Vanguard High Dividend Yield ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| GILD | VYM | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | — |
52-Week High | $155.80 | $161.17 |
52-Week Low | $108.22 | $132.90 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
VYM trades at $160.69, up 0.32% with a bullish technical outlook. Moving averages signal strength, while oscillators remain neutral. The ETF is highlighted in financial media for its role in retirement income strategies, offering broad diversification and a low expense ratio. Recent dividend activity includes a $0.98 distribution scheduled for June 2026.
The outlook for VYM is positive, supported by its income-generating appeal and cost efficiency. Risks include interest rate sensitivity and market volatility. Analyst sentiment leans favorable, with the ETF being a core holding for dividend-focused portfolios amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
